Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis

Bibliographic Details
Main Authors:	Bintou Ahmadou Ahidjo, William R. Bishai
Format:	Article
Language:	English
Published:	Elsevier 2016-02-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396416300494

Similar Items

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
by: Mamoudou Maiga, et al.
Published: (2012-01-01)

Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis
by: Anca Dorhoi
Published: (2015-08-01)

Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP
by: Akshay Rohilla, et al.
Published: (2024-01-01)

Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
by: Rafina Syfridiana, et al.
Published: (2021-08-01)

Phosphodiesterase Inhibitors: Present and Future
by: José L. Izquierdo-Alonso
Published: (2023-01-01)

Effect of phosphodiesterase inhibitors in the bladder
by: Bilal Chughtai, et al.
Published: (2015-01-01)

Adjunctive Integrated Stress Response Inhibition Accelerates Tuberculosis Clearance in Mice
by: Stefanie Krug, et al.
Published: (2023-04-01)

The use of phosphodiesterase inhibitors for the treatment of alopecia
by: Margit L. W. Juhász, et al.
Published: (2020-04-01)

New Avenues for Phosphodiesterase Inhibitors in Asthma
by: Matera MG, et al.
Published: (2021-03-01)

Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants
by: Amit K. Tiwari, et al.
Published: (2013-06-01)

The interaction between antimicrobial and adjunctive therapies and the immune response to tuberculosis
by: R. Wilkinson
Published: (2014-04-01)

Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis
by: Vinzeigh Leukes, et al.
Published: (2020-03-01)

VapC toxins from Mycobacterium tuberculosis are ribonucleases that differentially inhibit growth and are neutralized by cognate VapB antitoxins.
by: Bintou Ahmadou Ahidjo, et al.
Published: (2011-01-01)

Are phosphodiesterase type 5 inhibitors potential therapies for Alzheimer’s Disease and related dementias?
by: Newby, D
Published: (2022)

Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD
by: Anne B Taegtmeyer, et al.
Published: (2012-07-01)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
by: Heng Li, et al.
Published: (2018-10-01)

Effects of phosphodiesterase inhibitors on secretions of human monokines
by: Yuji Suda, et al.
Published: (1998-01-01)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
by: Viera Janosova, et al.
Published: (2020-07-01)

Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
by: Daniela Mokra, et al.
Published: (2021-02-01)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
by: Mauro Giorgi, et al.
Published: (2020-07-01)

Phosphodiesterase-4 inhibitor in the treatment of psoriasis and psoriatic arthritis
by: O. Yu. Olisova, et al.
Published: (2019-07-01)

Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors
by: Katharine H. Banner, et al.
Published: (1996-01-01)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
by: Theerasuk Kawamatawong
Published: (2021-08-01)

Use of phosphodiesterase 4 inhibitor in patients with psoriatic arthritis
by: V. I. Mazurov, et al.
Published: (2017-04-01)

The Manipulation of the Lipid Mediator Metabolism as Adjunct Host-Directed Therapy in Tuberculosis
by: Arista Nienaber, et al.
Published: (2021-03-01)

Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals
by: Samreen Fatima, et al.
Published: (2021-12-01)

Are There Sex-Specific Differences in Response to Adjunctive Host-Directed Therapies for Tuberculosis?
by: Noton K. Dutta, et al.
Published: (2020-07-01)

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
by: Florian Rieder, et al.
Published: (2013-01-01)

Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1
by: Xue Zhi Zhao, et al.
Published: (2022-08-01)

New Deoxycholic Acid Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitors Also Inhibit Tyrosyl-DNA Phosphodiesterase 2
by: Oksana V. Salomatina, et al.
Published: (2021-12-01)

Evaluation of the Therapeutic Index of a Novel Phosphodiesterase 4B– Selective Inhibitor Over Phosphodiesterase 4D in Mice
by: Osamu Suzuki, et al.
Published: (2013-01-01)

Adjunctive corticosteroids for all forms of tuberculosis?
by: Thwaites, G
Published: (2013)

Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease
by: Esther Nalini Honibald, et al.
Published: (2012-01-01)

Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors
by: R. A. McIvor
Published: (2007-09-01)

Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice
by: Da Hea Seo, et al.
Published: (2022-08-01)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
by: Ahmed K. ElHady, et al.
Published: (2023-09-01)

Beneficial effects of certain phosphodiesterase inhibitors on diabetes mellitus in rats
by: Mostafa El Sayed El Sayed, et al.
Published: (2014-12-01)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
by: Dunkern Torsten, et al.
Published: (2009-09-01)

Therapeutic utility of Phosphodiesterase type I inhibitors in neurological conditions.
by: Alexandre Esteves Medina
Published: (2011-02-01)

Evaluation of IL-1 Blockade as an Adjunct to Linezolid Therapy for Tuberculosis in Mice and Macaques
by: Caylin G. Winchell, et al.
Published: (2020-05-01)